Induction of multiple sclerosis and response to tyrosine kinase inhibitors

Indian Journal of Clinical Biochemistry

Volumn 29, Issue 4, 2014, Pages 491-495

  Moawad, Emad Y ^a,b  

^a Ain Shams University   (Egypt)

^b NONE   (Egypt)

Author keywords

Histologic grade; Platelet derived growth factor; Tumour necrotic factor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; INFLAMMATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RAT;

EID: 84901641921     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-013-0387-z     Document Type: Article

References (20)

1. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2:762-4.
2. Herndon RM. The pathology of multiple sclerosis. In: Herndon RM, editor. Multiple sclerosis: immunology, pathology and pathophysiology. New York: Demos Medical Publishing; 2003. p. 185-97.
3. Benveniste E. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med. 1997;75(3):165-73.
4. Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol. 2003;138:106-14.
5. Sayed BA, Christy AL, Walker ME, Brown MA. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment? J Immunol. 2010;184(12):6891-900.
6. Kieseier BC, Hemmer B, Hartung HP. Multiple sclerosis - novel insights and new therapeutic strategies. Curr Opin Neurol. 2005;18:211-20.
7. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006;116:2633-42.
8. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105(48):18895-900.
9. Moawad EY. Clinical and pathological staging of the cancer at the nanoscale. Cancer Nanotechnol. 2012;3:37-46.
10. Moawad EY. Reconciliation between the clinical and pathological staging of cancer. Comp Clin Pathol. 2012. doi: 10.1007/s00580-012-1603-6.
11. Moawad EY. Administering the optimum dose of L-Arginine in regional tumor therapy. Ind J Clin Biochem. 2013. doi: 10.1007/s12291-013-0379-z.
12. Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, Steinman L, Robinson WH. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol. 2011. doi: 10.1007/s10875-011-9579-6.
13. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005;26:565-71.
14. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1:1810.
15. Kenneth Barbalace. Periodic table of elements: Hydrogen (H). EnvironmentalChemistry.com. 1995-2011. Accessed on-line: 12/21/2011 http://EnvironmentalChemistry.com/yogi/periodic/H-pg2.html.
16. Moawad E. Isolated system towards a successful radiotherapy treatment. Nucl Med Mol Imaging. 2010;44:123-36.
17. Moawad EY. Radiotherapy and risks of tumor regrowth or inducing second cancer. Cancer Nanotechnol. 2011;2:81-93.
18. Moawad EY. Optimizing bioethanol production through regulating yeast growth energy. Syst Synth Biol. 2012;6:61-8.
19. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007;109(5):2147-55.
20. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345:340-50.